TMCnet News

Research and Markets: Congestive Heart Failure Partnering Deals and Agreements 2010-2015
[April 27, 2015]

Research and Markets: Congestive Heart Failure Partnering Deals and Agreements 2010-2015


Research and Markets (http://www.researchandmarkets.com/research/gxmr2j/congestive_heart) has announced the addition of the "Congestive Heart Failure Partnering 2010-2015" report to their offering.

The Congestive Heart Failure Partnering 2010-2015 provides understanding and access to the congestive heart failure partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of congestive heart failure partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors congestive heart failure technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in te detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.



This data driven report contains over 90 links to online copies of actual congestive heart failure deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

This data driven report includes:


  • Trends in congestive heart failure dealmaking in the biopharma industry since 2010
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 60 congestive heart failure deals and contract documents where available
  • The leading congestive heart failure deals by value since 2010

In Congestive Heart Failure Partnering 2010-2015, the available deals are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type

Companies Mentioned

  • Abbott
  • Amgen
  • Aspen Pharmacare
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Eli Lilly
  • Endo Pharmaceuticals
  • Forest Laboratories
  • GlaxoSmithKline
  • Grifols
  • Hospira
  • Johnson & Johnson
  • Merck & Co
  • Mitsubishi (News - Alert) Tanabe
  • Novartis
  • Novo Nordisk
  • Otsuka
  • Pfizer
  • Roche
  • Sanofi
  • Takeda
  • Teva

For more information visit http://www.researchandmarkets.com/research/gxmr2j/congestive_heart


[ Back To TMCnet.com's Homepage ]